Gregory John Hollingworth

Title: Gregory John Hollingworth: Innovator in Pharmaceutical Chemistry

Introduction

Gregory John Hollingworth is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as intermediates in the synthesis of important therapeutic agents.

Latest Patents

Hollingworth holds a patent for "Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors." This invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI). His innovative work in this area has the potential to impact the treatment of various diseases.

Career Highlights

Currently, Gregory John Hollingworth is associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to engage in cutting-edge research and development, contributing to advancements in medical science.

Collaborations

Hollingworth has collaborated with talented professionals in his field, including Luca Arista and Christina Hebach. These partnerships enhance the innovative capacity of his work and foster a collaborative environment for scientific discovery.

Conclusion

Gregory John Hollingworth is a distinguished inventor whose work in pharmaceutical chemistry exemplifies the importance of innovation in healthcare. His contributions, particularly in the synthesis of bruton's tyrosine kinase inhibitors, highlight the critical role of inventors in advancing medical treatments.